Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab plus platinum-gemcitabine versus placebo plus platinum-gemcitabine for locally advanced or metastatic urothelial carcinoma
CTR20190543Phase 3Active
- Sponsor
- BeOne Medicines
- Start
- May 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of tislelizumab in transitional cell carcinoma (TCC), sponsored by BeOne Medicines. Started May 2019; status: active.
02
Drugs
tislelizumab
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on CTR20190543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190543.